{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:46:11Z","timestamp":1792143971384,"version":"4.4.0"},"reference-count":115,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":230,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["5M-2023-23687106"],"award-info":[{"award-number":["5M-2023-23687106"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic arthropathies are major drivers of pain and disability, and an immunometabolic template is reshaping how osteoarthritis (OA) and inflammatory arthritis are conceptualized, linking systemic metabolic stress to synovial inflammation, cartilage catabolism and disease progression. Incretin-based therapies (GLP-1RAs and dual GLP-1R\/GIPR agonists) have revealed pleiotropic actions extending beyond weight loss and glycaemic control, supporting the concept of an \u2018incretin\u2013joint axis\u2019 with disease-modifying potential. Joint tissues appear capable of sensing incretin signalling, supporting a direct, receptor-mediated action within the joint. Across articular cell types, GLP-1RA exposure engages conserved stress-response pathways, reducing inflammation and catabolism in chondrocytes and modulating synovial fibroblast and macrophage activity in inflammatory arthritis. Early clinical data indicate improvements in OA symptoms with GLP-1R agonism; however, mechanistic attribution remains intertwined with weight reduction. Definitive translation will require receptor-centric mapping in human joint microenvironments and interventional designs disentangling direct joint actions from weight-mediated benefit.<\/jats:p>","DOI":"10.1093\/rap\/rkag105","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:32:45Z","timestamp":1787052765000},"source":"Crossref","is-referenced-by-count":0,"title":["The incretin\u2013joint axis: weight-independent mechanisms and disease-modifying potential in chronic arthropathies"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6986-3898","authenticated-orcid":false,"given":"Nefeli Stavroula","family":"Papastathopoulou","sequence":"first","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3257-6293","authenticated-orcid":false,"given":"Simona","family":"Neri","sequence":"additional","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-6506","authenticated-orcid":false,"given":"Elisa","family":"Assirelli","sequence":"additional","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-0014","authenticated-orcid":false,"given":"Andrea","family":"D\u2019Amuri","sequence":"additional","affiliation":[{"name":"General Medicine Unit, ASST Mantova\u2014Ospedale Carlo Poma , Mantova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-0135","authenticated-orcid":false,"given":"Salvatore","family":"Greco","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Ospedale del Delta , Lagosanto,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-7351","authenticated-orcid":false,"given":"Jacopo","family":"Ciaffi","sequence":"additional","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]},{"name":"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-8642","authenticated-orcid":false,"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[{"name":"Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]},{"name":"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026101605072432300_rkag105-B1","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Osteoarthritis Collaborators","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026101605072432300_rkag105-B2","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Rheumatoid Arthritis Collaborators","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026101605072432300_rkag105-B3","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s10067-025-07637-z","article-title":"Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis","volume":"44","author":"Andreasson","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026101605072432300_rkag105-B4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fphys.2020.00347","article-title":"Metabolic checkpoints in rheumatoid arthritis","volume":"11","author":"Pucino","year":"2020","journal-title":"Front Physiol"},{"key":"2026101605072432300_rkag105-B5","doi-asserted-by":"crossref","first-page":"907750","DOI":"10.3389\/fimmu.2022.907750","article-title":"Obesity, inflammation, and immune system in osteoarthritis","volume":"13","author":"Nedunchezhiyan","year":"2022","journal-title":"Front Immunol"},{"key":"2026101605072432300_rkag105-B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"Npj Metab Health Dis"},{"key":"2026101605072432300_rkag105-B7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101605072432300_rkag105-B8","doi-asserted-by":"crossref","first-page":"e006025","DOI":"10.1136\/rmdopen-2025-006025","article-title":"If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?","volume":"11","author":"Ursini","year":"2025","journal-title":"RMD Open"},{"key":"2026101605072432300_rkag105-B9","author":"University of Melbourne","year":"2025"},{"key":"2026101605072432300_rkag105-B10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101605072432300_rkag105-B11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026101605072432300_rkag105-B12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1507\/endocrj.EJ25-0087","article-title":"Physiology and clinical applications of GIP","volume":"72","author":"Yamane","year":"2025","journal-title":"Endocr J"},{"key":"2026101605072432300_rkag105-B13","volume-title":"StatPearls","author":"Patel","year":"2025"},{"key":"2026101605072432300_rkag105-B14","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"2026101605072432300_rkag105-B15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026101605072432300_rkag105-B16","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026101605072432300_rkag105-B17","doi-asserted-by":"crossref","first-page":"678055","DOI":"10.3389\/fendo.2021.678055","article-title":"The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells","volume":"12","author":"Marzook","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026101605072432300_rkag105-B18","doi-asserted-by":"crossref","first-page":"171179","DOI":"10.1016\/j.peptides.2024.171179","article-title":"GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells","volume":"175","author":"Shilleh","year":"2024","journal-title":"Peptides"},{"key":"2026101605072432300_rkag105-B19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2026101605072432300_rkag105-B20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12065","article-title":"Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas","volume":"4","author":"Seino","year":"2013","journal-title":"J Diabetes Investig"},{"key":"2026101605072432300_rkag105-B21","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1159\/000430199","article-title":"The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP\/PKA\/CREB pathway","volume":"36","author":"Bao","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"2026101605072432300_rkag105-B22","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1111\/dom.70458","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: an updated meta-analysis including the SOUL trial","volume":"28","author":"Hasebe","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026101605072432300_rkag105-B23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-025-01302-0","article-title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","volume":"21","author":"Karacabeyli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"2026101605072432300_rkag105-B24","volume-title":"StatPearls","author":"Collins","year":"2024"},{"key":"2026101605072432300_rkag105-B25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.14775","article-title":"Efficacy of tirzepatide 5, 10 and 15\u2009mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison","volume":"24","author":"Vadher","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026101605072432300_rkag105-B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101605072432300_rkag105-B27","doi-asserted-by":"crossref","first-page":"107516","DOI":"10.1016\/j.cct.2024.107516","article-title":"Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial","volume":"141","author":"Malhotra","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"2026101605072432300_rkag105-B28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101605072432300_rkag105-B29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chest.2025.03.030","article-title":"Clinical impact of tirzepatide on patients with OSA and obesity","volume":"168","author":"Wu","year":"2025","journal-title":"Chest"},{"key":"2026101605072432300_rkag105-B30","first-page":"eadt0548","article-title":"Osteoarthritis treatment via the GLP-1\u2013mediated gut-joint axis targets intestinal FXR signaling","volume":"388","author":"Yang","year":"2025","journal-title":"Science (1979)"},{"key":"2026101605072432300_rkag105-B31","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"key":"2026101605072432300_rkag105-B32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","article-title":"Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026101605072432300_rkag105-B33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12950-019-0218-y","article-title":"The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis","volume":"16","author":"Que","year":"2019","journal-title":"J Inflamm (Lond)"},{"key":"2026101605072432300_rkag105-B34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jor.26050","article-title":"The anti-inflammatory effects of liraglutide in equine inflammatory joint models","volume":"43","author":"Scheike","year":"2025","journal-title":"J Orthop Res"},{"key":"2026101605072432300_rkag105-B35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2026101605072432300_rkag105-B36","doi-asserted-by":"crossref","first-page":"e5826","DOI":"10.1590\/1414-431x20165826","article-title":"Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages","volume":"49","author":"Guo","year":"2016","journal-title":"Braz J Med Biol Res."},{"key":"2026101605072432300_rkag105-B37","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"key":"2026101605072432300_rkag105-B38","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"2026101605072432300_rkag105-B39","doi-asserted-by":"crossref","first-page":"keag147","DOI":"10.1093\/rheumatology\/keag147","article-title":"Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases","volume":"65","author":"Karacabeyli","year":"2026","journal-title":"Rheumatol Oxf Engl"},{"key":"2026101605072432300_rkag105-B40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"2026101605072432300_rkag105-B41","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026101605072432300_rkag105-B42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","article-title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","volume":"53","author":"Hadjiyanni","year":"2010","journal-title":"Diabetologia"},{"key":"2026101605072432300_rkag105-B43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2026101605072432300_rkag105-B44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-022-01486-9","article-title":"Liraglutide preserves CD34+ stem cells from dysfunction induced by high glucose exposure","volume":"21","author":"Sforza","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026101605072432300_rkag105-B45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s42255-018-0001-z","article-title":"GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8\/A9","volume":"1","author":"Mantelmacher","year":"2019","journal-title":"Nat Metab"},{"key":"2026101605072432300_rkag105-B46","doi-asserted-by":"crossref","first-page":"101008","DOI":"10.1016\/j.molmet.2020.101008","article-title":"The gut hormone receptor GIPR links energy availability to the control of hematopoiesis","volume":"39","author":"Pujadas","year":"2020","journal-title":"Mol Metab"},{"key":"2026101605072432300_rkag105-B47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.peptides.2014.11.009","article-title":"Regulation of nutrition-associated receptors in blood monocytes of normal weight and obese humans","volume":"65","author":"Pivovarova","year":"2015","journal-title":"Peptides"},{"key":"2026101605072432300_rkag105-B48","doi-asserted-by":"crossref","first-page":"e35683","DOI":"10.1371\/journal.pone.0035683","article-title":"Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice","volume":"7","author":"Nogi","year":"2012","journal-title":"PLoS One"},{"key":"2026101605072432300_rkag105-B49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3892\/ijmm.2014.1787","article-title":"Expression of glucagon-like peptide-1 receptor and glucose\u2011dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells","volume":"34","author":"Aoyama","year":"2014","journal-title":"Int J Mol Med"},{"key":"2026101605072432300_rkag105-B50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","article-title":"Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin","volume":"6","author":"Meng","year":"2016","journal-title":"Stem Cell Rep"},{"key":"2026101605072432300_rkag105-B51","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jcp.22243","article-title":"Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor","volume":"225","author":"Nuche-Berenguer","year":"2010","journal-title":"J Cell Physiol"},{"key":"2026101605072432300_rkag105-B52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6793-11-12","article-title":"Receptors and effects of gut hormones in three osteoblastic cell lines","volume":"11","author":"Pacheco-Pantoja","year":"2011","journal-title":"BMC Physiol"},{"key":"2026101605072432300_rkag105-B53","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3803\/EnM.2014.29.4.567","article-title":"Expression of glucagon-like peptide 1 receptor during osteogenic differentiation of adipose-derived stem cells","volume":"29","author":"Jeon","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2026101605072432300_rkag105-B54","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.141.3.7366","article-title":"Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors","volume":"141","author":"Bollag","year":"2000","journal-title":"Endocrinology"},{"key":"2026101605072432300_rkag105-B55","doi-asserted-by":"crossref","first-page":"lvac004","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026101605072432300_rkag105-B56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/en.2007-1292","article-title":"The murine glucagon-like peptide-1 receptor is essential for control of bone resorption","volume":"149","author":"Yamada","year":"2008","journal-title":"Endocrinology"},{"key":"2026101605072432300_rkag105-B57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/JOE-13-0146","article-title":"Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor","volume":"219","author":"Mabilleau","year":"2013","journal-title":"J Endocrinol"},{"key":"2026101605072432300_rkag105-B58","doi-asserted-by":"crossref","first-page":"5783639","DOI":"10.1155\/2018\/5783639","article-title":"The glucagon-like peptide-1 receptor agonist exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of tnf-\u03b1 expression in macrophages","volume":"2018","author":"Shen","year":"2018","journal-title":"J Immunol Res"},{"key":"2026101605072432300_rkag105-B59","doi-asserted-by":"crossref","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"2026101605072432300_rkag105-B60","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1152\/ajpendo.00364.2006","article-title":"Effects of glucose-dependent insulinotropic peptide on osteoclast function","volume":"292","author":"Zhong","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026101605072432300_rkag105-B61","doi-asserted-by":"crossref","first-page":"E634","DOI":"10.1152\/ajpendo.00460.2009","article-title":"Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow","volume":"298","author":"Sanz","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026101605072432300_rkag105-B62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrrheum.2016.65","article-title":"Ageing and the pathogenesis of osteoarthritis","volume":"12","author":"Loeser","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2026101605072432300_rkag105-B63","first-page":"3089","article-title":"Glucose-dependent insulinotropic polypeptide receptor deficiency leads to impaired bone marrow hematopoiesis","volume":"198","author":"Mantelmacher","year":"2017","journal-title":"J Immunol Baltim MD 1950"},{"key":"2026101605072432300_rkag105-B64","doi-asserted-by":"crossref","first-page":"116010","DOI":"10.1016\/j.intimp.2025.116010","article-title":"GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK\/SIRT1 pathway","volume":"169","author":"Zhang","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"2026101605072432300_rkag105-B65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diff.2021.05.001","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 induces tenogenesis in human mesenchymal stem cells","volume":"120","author":"Abdulmalik","year":"2021","journal-title":"Differentiation"},{"key":"2026101605072432300_rkag105-B66","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"2026101605072432300_rkag105-B67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026101605072432300_rkag105-B68","doi-asserted-by":"crossref","first-page":"1463547","DOI":"10.3389\/fendo.2024.1463547","article-title":"Anti-atherosclerotic effect of incretin receptor agonists","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026101605072432300_rkag105-B69","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026101605072432300_rkag105-B70","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/acr2.70103","article-title":"Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis","volume":"7","author":"Kellner","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026101605072432300_rkag105-B71","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1210\/en.2018-00336","article-title":"Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial remodeling in male mice","volume":"159","author":"Mori","year":"2018","journal-title":"Endocrinology"},{"key":"2026101605072432300_rkag105-B72","doi-asserted-by":"crossref","first-page":"108968","DOI":"10.1016\/j.cbi.2020.108968","article-title":"The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes","volume":"322","author":"Li","year":"2020","journal-title":"Chem Biol Interact"},{"key":"2026101605072432300_rkag105-B73","first-page":"4800","article-title":"Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis","volume":"11","author":"Mei","year":"2019","journal-title":"Am J Transl Res"},{"key":"2026101605072432300_rkag105-B74","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12891-024-07640-6","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"2026101605072432300_rkag105-B75","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1080\/21691401.2019.1593996","article-title":"Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes","volume":"47","author":"Li","year":"2019","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"key":"2026101605072432300_rkag105-B76","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/iub.2031","article-title":"Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"71","author":"Tao","year":"2019","journal-title":"IUBMB Life"},{"key":"2026101605072432300_rkag105-B77","doi-asserted-by":"crossref","first-page":"105649","DOI":"10.1016\/j.intimp.2019.05.034","article-title":"Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes","volume":"74","author":"Zheng","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026101605072432300_rkag105-B78","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.intimp.2019.105732","article-title":"The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"75","author":"Du","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026101605072432300_rkag105-B79","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1186\/s12967-023-04772-6","article-title":"The role of AMPK in macrophage metabolism, function and polarisation","volume":"21","author":"Cui","year":"2023","journal-title":"J Transl Med"},{"key":"2026101605072432300_rkag105-B80","doi-asserted-by":"crossref","first-page":"13435","DOI":"10.1523\/JNEUROSCI.3257-09.2009","article-title":"Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord","volume":"29","author":"Kigerl","year":"2009","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"2026101605072432300_rkag105-B81","doi-asserted-by":"crossref","first-page":"1342944","DOI":"10.3389\/fnins.2024.1342944","article-title":"The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype","volume":"18","author":"Noguchi","year":"2024","journal-title":"Front Neurosci"},{"key":"2026101605072432300_rkag105-B82","doi-asserted-by":"crossref","first-page":"697442","DOI":"10.3389\/fphar.2021.697442","article-title":"The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment","volume":"12","author":"Xie","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026101605072432300_rkag105-B83","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1007\/s00210-024-03378-z","article-title":"The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis","volume":"398","author":"Abo-Elenin","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026101605072432300_rkag105-B84","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1210\/me.2005-0187","article-title":"Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion","volume":"20","author":"Tsukiyama","year":"2006","journal-title":"Mol Endocrinol Baltim MD"},{"key":"2026101605072432300_rkag105-B85","doi-asserted-by":"crossref","first-page":"106058","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026101605072432300_rkag105-B86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"2026101605072432300_rkag105-B87","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101605072432300_rkag105-B88","doi-asserted-by":"crossref","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"2026101605072432300_rkag105-B89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.regpep.2011.11.008","article-title":"GLP-1 analogue, liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress","volume":"174","author":"Schisano","year":"2012","journal-title":"Regul Pept"},{"key":"2026101605072432300_rkag105-B90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026101605072432300_rkag105-B91","doi-asserted-by":"crossref","first-page":"103414","DOI":"10.1016\/j.jaut.2025.103414","article-title":"Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases","volume":"153","author":"Yang","year":"2025","journal-title":"J Autoimmun"},{"key":"2026101605072432300_rkag105-B92","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ard.2025.08.013","article-title":"Antiobesity medications in rheumatology. Quo vadis?","volume":"85","author":"Kyriazi","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026101605072432300_rkag105-B93","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026101605072432300_rkag105-B94","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fimmu.2020.00955","article-title":"Editorial: immunomodulatory functions of fibroblast-like synoviocytes in joint inflammation and destruction during rheumatoid arthritis","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"2026101605072432300_rkag105-B95","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/art.70044","article-title":"Glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and risk of autoimmune rheumatic diseases","volume":"78","author":"Karacabeyli","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026101605072432300_rkag105-B96","volume-title":"Endocrine abstracts","author":"Gavazova","year":"2024"},{"key":"2026101605072432300_rkag105-B97","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026101605072432300_rkag105-B98","author":"Faurschou","year":"2013"},{"key":"2026101605072432300_rkag105-B99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","article-title":"Improvement of psoriasis during exenatide treatment in a patient with diabetes","volume":"38","author":"Buysschaert","year":"2012","journal-title":"Diabetes Metab"},{"key":"2026101605072432300_rkag105-B100","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00228-025-03898-4","article-title":"GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management\u2013current evidence and future outlook","volume":"81","author":"Atiquzzaman","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"2026101605072432300_rkag105-B101","doi-asserted-by":"crossref","first-page":"501809","DOI":"10.1016\/j.reuma.2024.501809","article-title":"Effects of liraglutide among patients with psoriatic arthritis and obesity","volume":"21","author":"Nicolau","year":"2025","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2026101605072432300_rkag105-B102","doi-asserted-by":"crossref","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026101605072432300_rkag105-B103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00011-025-02140-2","article-title":"The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review","volume":"74","author":"Buonanno","year":"2025","journal-title":"Inflamm Res"},{"key":"2026101605072432300_rkag105-B104","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.joca.2010.08.016","article-title":"Circulating levels of IL-6 and TNF-\u03b1 are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults","volume":"18","author":"Stannus","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"2026101605072432300_rkag105-B105","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101605072432300_rkag105-B106","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12178-025-09978-3","article-title":"The effects of GLP-1 agonists on musculoskeletal health and orthopedic care","volume":"18","author":"Gatto","year":"2025","journal-title":"Curr Rev Musculoskelet Med"},{"key":"2026101605072432300_rkag105-B107","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","article-title":"Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis","volume":"62","author":"Tan","year":"2025","journal-title":"Acta Diabetol"},{"key":"2026101605072432300_rkag105-B108","doi-asserted-by":"crossref","first-page":"e3843","DOI":"10.1002\/dmrr.3843","article-title":"Effects of glucagon-like peptide-1 receptor agonist on bone mineral density and bone turnover markers: a meta-analysis","volume":"40","author":"Kim","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"2026101605072432300_rkag105-B109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/phar.70005","article-title":"The potential role of GLP-1 receptor agonists in osteoarthritis","volume":"45","author":"Ryan","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026101605072432300_rkag105-B110","first-page":"e93373","article-title":"Glucagon-like peptide-1 receptor agonists for arthritis and osteoarthritis","volume":"17","author":"Nashwan","year":"2025","journal-title":"Cureus"},{"key":"2026101605072432300_rkag105-B111","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.joca.2025.06.011","article-title":"Beyond weight loss: GLP-1 emerges as a disease-modifying signal in osteoarthritis","volume":"33","author":"Berenbaum","year":"2025","journal-title":"Osteoarthritis Cartilage"},{"key":"2026101605072432300_rkag105-B112","doi-asserted-by":"crossref","first-page":"iv10","DOI":"10.1093\/rheumatology\/kex399","article-title":"The role of fat and inflammation in the pathogenesis and management of osteoarthritis","volume":"57","author":"Urban","year":"2018","journal-title":"Rheumatology"},{"key":"2026101605072432300_rkag105-B113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"2026101605072432300_rkag105-B114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41419-023-05641-2","article-title":"Elevated fatty acid \u03b2-oxidation by leptin contributes to the proinflammatory characteristics of fibroblast-like synoviocytes from RA patients via LKB1-AMPK pathway","volume":"14","author":"Wei","year":"2023","journal-title":"Cell Death Dis"},{"key":"2026101605072432300_rkag105-B115","doi-asserted-by":"crossref","first-page":"672519","DOI":"10.3389\/fimmu.2021.672519","article-title":"Insulin signaling in arthritis","volume":"12","author":"Tripolino","year":"2021","journal-title":"Front Immunol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag105\/70688786\/rkag105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/4\/rkag105\/70688786\/rkag105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/4\/rkag105\/70688786\/rkag105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:07:43Z","timestamp":1792141663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag105\/8764146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag105","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag105"}}